Attenuation of paraquat-induced motor behavior and neurochemical disturbances by L-valine in vivo

Toxicology Letters

Volumn 150, Issue 3, 2004, Pages 259-269

  Chanyachukul, Thida ^a   Yoovathaworn, Krongtong ^a   Thongsaard, Watchareewan ^b   Chongthammakun, Sukumal ^a   Navasumrit, Panida ^c   Satayavivad, Jutamaad ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c Toxicology and Management of Chemicals   (Thailand)

^d Chulabhorn Research Institute   (Thailand)

Author keywords

Dopamine metabolites; L Valine; Monoamine; Motor behavior; Paraquat

Indexed keywords

DOPAMINE; MONOAMINE; NORADRENALIN; PARAQUAT; VALINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; HYPOTHALAMUS; LOCOMOTION; MALE; METABOLITE; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HERBICIDES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; NOREPINEPHRINE; PARAQUAT; RATS; RATS, WISTAR; VALINE;

EID: 1942517470     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2004.02.007     Document Type: Article

References (46)

1. Bagetta G., Corasaniti M.T., Iannone M., Nistico G., Stepenson J.D. Production of limbic motor seizures and brain damage by systemic and intracerebral injections of paraquat in rats. Pharmacol. Toxicol. 71:1992;443-448.
2. Bagetta G., Iannone M., Vecchio I., Rispoli V., Rotiroti D., Nistico G. Neurodegeneration produced by intrahippocampal injection of paraquat is reduced by systemic administration of the 21-aminosteroid U74389F in rats. Free Radic. Res. 21:1994;85-93.
3. Bates I.P. Permeability of the blood-brain barrier. Trends Pharmacol. Sci. 6:1985;447-450.
4. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioural syndrome caused by dopaminergic neuron loss. Brain Res. 823:1999;1-10.
5. Bus J.S., Gibson J.E. Paraquat: model for oxidant-initiated toxicity. Environ. Health Perspect. 55:1984;37-46.
6. Calo M., Iannone M., Passafaro M., Nistico G. Selective vulnerability of hippocampal CA3 neurons after microinfusion of paraquat into the rat substantia nigra or into the ventral tegmental area. J. Comp. Pathol. 103:1990;73-78.
7. Corasaniti M.T., Bagetta G., Rodino P., Gratteri S., Nistico G. Neurotoxic effect induced by intracerebral and systemic injection of paraquat in rats. Hum. Exp. Toxicol. 11:1992;535-539.
8. Corasaniti M.T., Nistico G. Determination of paraquat in rat brain by high-performance liquid chromatography. J. Chromatogr. 643:1993;419-425.
9. Dey M.S., Breeze R.G., Hayton W.L., Karara A.H., Krieger R.I. Paraquat pharmacokinetics using a subcutaneous toxic low dose in the rat. Fundam. Appl. Toxicol. 14:1990;208-216.
10. Dey M.S., Krieger R.I., Ritter R.C. Paraquat-induced, dose-dependent conditioned taste aversions and weight loss mediated by the area postrema. Toxicol. Appl. Pharmacol. 87:1987;212-221.
11. Edmonds B.K., Edwards G.L. The area postrema is involved in paraquat-induced conditioned aversion behavior and neuroendocrine activation of the hypothalamic-pituitary-adrenal axis. Brain Res. 712:1996;127-133.
12. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
13. Fredriksson A., Archer T. MPTP-induced behavioral and biochemical deficits: a parametric analysis. J. Neural. Transm. Park. Dis. Dement. Sect. 7:1994;123-132.
14. Fredriksson A., Fredriksson M., Eriksson P. Neonatal exposure of MPTP induces permanent changes in striatum dopamine and behavior in adult mice. Toxicol. Appl. Pharmacol. 122:1993;258-264.
15. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain I. J. Neurochem. 13:1966;655-669.
16. Hara S., Iwata N., Kuriiwa F., Kano S., Kawaguchi N., Endo T. Involvement of opioid receptors in shaking behavior induced by paraquat in rats. Pharmacol. Toxicol. 73:1993;146-149.
17. Hara S., Mukai T., Kurosaki K., Kuiiwa F., Yanase T., Kano S., Endo T. No parallel relationship between nitric oxide production and wet dog shakes susceptible to nitric oxide synthase inhibitors following systemic administration of paraquat in rats. Arch. Toxicol. 74:2001;775-782.
18. Hefti F., Enz A., Melamed E. Partial lesions of the nigrostriatal pathway in the rats. Neuropharmacology. 24:1985;19-23.
19. Hertzman C., Wiens M., Bowering D., Snow B., Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17:1990;349-355.
20. Ho S.C., Woo J., Lee C.M. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology. 39:1989;1314-1318.
21. Honchar M.P., Olney J.W., Sherman W.R. Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science. 220:1983;323-325.
22. Krauchi K., Wirz-Justice A., Morimasa T., Willener R., Feer H. Hypothalamic α2- and β-adrenoceptor rhythms are correlated with circadian feeding: evidence from chronic methamphetamine treatment and withdrawal. Brain Res. 321:1984;83-90.
23. Lindquist N.G., Larsson B.S., Lyden-Sokolowski A. Autoradiography of [14C] paraquat or [14C] diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93:1988;1-6.
24. Liou H.H., Chen R.C., Chen T.H.H., Tsai Y.F., Tsai M.C. Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo. Toxicol. Appl. Pharmacol. 172:2001;37-43.
25. Liou H.H., Chen R.C., Tsai Y.F., Chen W.P., Chang Y.C., Tsai M.C. Effects of paraquat on the substantia nigra of the Wistar rats: neurochemical, histological, and behavioural studies. Toxicol. Appl. Pharmacol. 137:1996;34-41.
26. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology. 48:1997;1583-1588.
27. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. J. Biol. Chem. 277:2002;1641-1644.
28. McCormack A.L., Di Monte D. Effect of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J. Neurochem. 85:2003;82-86.
29. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D. Environmental risk factors and Parkinson's disease: selective degenerartion of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10:2002;119-127.
30. Naylor J.L., Widdowson P.S., Simpson M.G., Farnworth M., Ellis M.K., Lock E.A. Further evidence that the blood/brain barrier impeded paraquat entry into the brain. Hum. Exp. Toxicol. 14:1995;587-594.
31. Ogawa N., Hirose Y., Ohara S., Ono T., Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50:1985;435-441.
32. Perry T.L., Yong V.W., Wall R.A., Jones K. Paraquat and two endogenous analogues of the neurortoxic substance N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 69:1986;285-289.
33. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods. 245:1998;151-154.
34. Satayavivad J., Siripat W., Thiantanawat A. Neurological effects of chronic exposure to low doses of paraquat in rats. Res. Commun. Biol. Psychol. Psychi. 2:1997;269-282.
35. Sedelis M., Hofele K., Auberger G.W., Morgan S., Huston J.P., Schwarting R.K.W. MPTP susceptibility in the mouse: behavioral, neurochemical and histological analysis of gender and strain differences. Behav. Genet. 30:2000;171-182.
36. Seto Y., Shinohara T. Inhibitory effects of paraquat and its related compounds on the acetylcholinesterase activities of human erythrocytes and electric eel, Electrophorus electricus. Agric. Biol. Chem. 51:1987;2131-2138.
37. Seto Y., Shinohara T. Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch. Toxicol. 62:1988;37-40.
38. Shimizu K., Matsubara K., Ohtaki K., Fujimura S., Saito O., Shiono H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res. 976:2003;243-252.
39. Shimizu K., Ohtaki K., Matsubara K., Aoyama K., Uezono T., Saito O., Suno M., Ogawa K., Hayase N., Kimura K., Shiono H. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res. 906:2001;135-142.
40. Shinohara T., Seto Y. In vitro inhibition of acetylcholinesterase by paraquat. Agric. Biol. Chem. 50:1986;255-256.
41. Sirinathsinghji D.J.S., Heavens R.P., Richards S.J., Beresford I.J.M., Hall M.D. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway-1. Behavioral, neurochemical and histological characterization of the lesion. Neuroscience. 27:1988;117-128.
42. Smith Q.R. Transport of glutamate and other amino acids at the blood-brain barrier. J. Nutr. 130:2000;1016S-1022S.
43. Tawara T., Fukushima T., Hojo N., Isobe A., Shiwaku K., Setogawa T., Yamane Y. Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain. Arch. Toxicol. 70:1996;585-589.
44. Thiruruchelvam M., Richfield F.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20:2000;9207-9214.
45. Van der Gugten J., De Kloet E.R., Versteeg D.H.G., Slangen J.L. Regional hypothalamic catecholamine metabolism and food intake regulation in the rat. Brain Res. 135:1977;325-336.
46. Widdowson P.S., Farnworth M.J., Simpson M.G., Lock E.A. Influence of age on the passage of paraquat through the blood-brain barrier in rats: A distribution and pathological examination. Hum. Exp. Toxicol. 15:1996;231-236.